Table 1 Clinicopathological features of the entire cohort stratified by response to NACI (pathologic complete response versus non-pathologic complete response)

From: Predictors of response to neoadjuvant chemo-immunotherapy in metaplastic triple-negative breast cancer

Characteristic

pCR

N = 7a

Residual Disease

N = 25a

p-valueb

Ethnicity

  

> 0.9

 Hispanic or Latino

0 (0%)

2 (8.0%)

 

 Not Hispanic or Latino

7 (100%)

23 (92%)

 

Race

  

0.2

 Asian

0 (0%)

3 (12%)

 

 Black

4 (57%)

5 (20%)

 

 White

3 (43%)

17 (68%)

 

Menopausal Status

  

0.6

 Post

4 (57%)

18 (72%)

 

 Pre

3 (43%)

7 (28%)

 

Age at diagnosis

  

0.8

 Median (IQR)

52 (48, 63)

57 (50, 62)

 

 [Range]

[33, 85]

[26, 83]

 

Nuclear Grade

  

> 0.9

 II

0 (0%)

2 (8.0%)

 

 III

7 (100%)

23 (92%)

 

Metaplastic Subtype

  

0.5

 Chondromyxoid/Matrix-Producing

4 (57%)

9 (36%)

 

 Mixed

2 (29%)

4 (16%)

 

 Spindle

0 (0%)

3 (12%)

 

 Squamous

1 (14%)

9 (36%)

 

Clinical Stage

  

0.4

 I

0 (0%)

4 (16%)

 

 II

7 (100%)

18 (72%)

 

 III

0 (0%)

3 (12%)

 

T stage at diagnosis

  

0.6

 T1c

2 (29%)

4 (16%)

 

 T2

5 (71%)

18 (72%)

 

 T3

0 (0%)

3 (12%)

 

N stage at diagnosis

  

0.10

 N0

4 (57%)

22 (88%)

 

 N1-N2

3 (43%)

3 (12%)

 

Ki-67 (cutoff)

  

> 0.9

 < 35

1 (50%)

4 (29%)

 

 ≥ 35

1 (50%)

10 (71%)

 

 Unknown

5

11

 

Completed NACI

  

0.4

 No

3 (43%)

17 (68%)

 

 Yes

4 (57%)

8 (32%)

 

Order of NACI first

  

0.6

 AC

1 (14%)

8 (32%)

 

 Carbo

6 (86%)

17 (68%)

 

RCB Status

   

 RCB-I

NA

1

 

 RCB-II

NA

20

 

 RCB-III

NA

4

 

PD-L1 CPS (cutoff - 10)

  

0.13

 < 10

0 (0%)

5 (38%)

 

 ≥ 10

6 (100%)

8 (62%)

 

 Unknown

1

12

 

PD-L1 CPS (cutoff - 1)

  

> 0.9

 < 1

0 (0%)

1 (7.7%)

 

 ≥ 1

6 (100%)

12 (92%)

 

 Unknown

1

12

 

sTIL (cutoff - 20)

  

0.3

 < 20%

0 (0%)

4 (31%)

 

 ≥ 20%

6 (100%)

9 (69%)

 

 Unknown

1

12

 

sTIL (cutoff - 30)

  

0.3

 < 30%

1 (17%)

6 (46%)

 

 ≥ 30%

5 (83%)

7 (54%)

 

 Unknown

1

12

 

sTIL (cutoff - 60)

  

0.041

 < 60%

1 (17%)

10 (77%)

 

 ≥ 60%

5 (83%)

3 (23%)

 

 Unknown

1

12

 
  1. pCR pathologic complete response, IQR interquartile range, NACI neoadjuvant chemo-immunotherapy, AC doxorubicin and cyclophosphamide, Pembro pembrolizumab, PD-L1 programmed death ligand 1, CPS combined positive score, sTIL stromal tumor-infiltrating lympohocyte.
  2. an (%).
  3. bFisher’s exact test; Wilcoxon rank sum test.